Date: 2015-02-03
Type of information: Services contract
Compound:
Company: Theradiag (France) UCB (Belgium)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
Type agreement: services
Action mechanism:
Disease:
Details: * On February 3, 2015, Theradiag, a company specializing in theranostics and in vitro diagnostics, announces that it has entered into a master services agreement with the biopharmaceutical company UCB, with a first application for the anti-TNF biologic certolizumab pegol (the brand name Cimzia®). Under the terms of the master services agreement, Theradiag will perform services for UCB on a project basis. A first project has already been conducted to determine the comparability of Theradiag’s LISA TRACKER tests with tests performed by UCB in clinical trials for the monitoring of drug levels and anti-drug antibodies in human plasma. The results of this performance study confirmed the suitability of Theradiag’s theranostic kit for monitoring patients treated with certolizumab pegol. The study was sponsored by UCB.
Financial terms:
Latest news:
